Compounded tirzepatide can be legal, but only inside rules that tightened once FDA declared the shortage over. Since early 2025, a pharmacy cannot lawfully turn out routine copies of the approved drug for anyone who asks[1][2].
Tirzepatide is the active ingredient in Zepbound and Mounjaro. The compounded version is made by a pharmacy rather than the drug's maker, and it has not been through FDA review.[6] How the two kinds of compounder differ is explained in 503A vs 503B.
The market has not disappeared. 361 sellers publish a monthly compounded tirzepatide injection price, with a typical figure of $249, read through September 2026. Whether each one is lawful turns on the rules below, not on the price.
How the shortage ruling changed things
Tirzepatide injection went onto FDA’s shortage list on December 15, 2022[1]. While a drug is in shortage, FDA does not treat it as commercially available, so the copy limits do not bite[2].
Dec 2022
Shortage listed
Tirzepatide injection products added to FDA's shortage list.
Oct 2024
First resolution, then remand
FDA removed it from the list; after a compounders' lawsuit, the court sent the decision back to FDA to re-evaluate.
Dec 2024
Declaratory order
FDA re-evaluated and again found the shortage resolved.
Feb 2025
503A grace period ends
End of FDA's stated forbearance for state-licensed pharmacies and physicians.
Mar 2025
503B grace period ends
End of FDA's stated forbearance for outsourcing facilities.
The order of December 19, 2024 found that Lilly’s supply met or exceeded demand[1]. It gave compounders a transition. State-licensed pharmacies and physicians had until February 18, 2025, and outsourcing facilities until March 19, 2025[1].
The October 2024 suit was brought in the Northern District of Texas by the Outsourcing Facilities Association and a compounding pharmacy[1]. The order also says FDA can still act against a compounded product for quality or safety problems at any time[1].
What a state pharmacy may still make
A state-licensed 503A pharmacy loses its exemption if it compounds, regularly or in inordinate amounts, drugs that are essentially copies of a commercially available product[2].
FDA’s guidance treats a compounded drug as essentially a copy when it has the same active ingredient, a similar or easily substitutable strength, and the same route[2]. That describes a weekly tirzepatide injection at a label dose.
There is one exception. A prescriber can determine that a change, made for an identified patient, produces a significant difference for that patient[2]. FDA’s example is a patient allergic to an inactive ingredient in the approved product[2].
So a compounded tirzepatide with an added vitamin is not automatically lawful. What matters is whether a prescriber recorded a significant difference for the individual patient. Prices for those mixes sit in the compounded tirzepatide cost guide.
What an outsourcing facility may make
A 503B outsourcing facility generally cannot compound from bulk active ingredient unless the substance is on the 503B bulks list, or the drug is on FDA’s shortage list[4]. With the shortage over, the list is the remaining route.
On May 1, 2026, FDA proposed not to include tirzepatide, semaglutide or liraglutide on that list[3]. FDA said it did not identify a clinical need for outsourcing facilities to compound them from bulk[4]. The comment period was extended to July 30, 2026[5], and FDA said it would weigh comments before a final determination[4].
What is clearly not legal
FDA has warned companies selling tirzepatide labeled “for research purposes” or “not for human consumption” directly to consumers with dosing instructions[6]. It has also found fraudulent products whose labels name pharmacies that did not make them, or that do not exist[6].
Through May 31, 2026, FDA had received more than 730 adverse event reports tied to compounded tirzepatide[6]. FDA notes that 503A pharmacies are not required to report adverse events, so the count is likely low[6].
If you are weighing a compounded vial against the approved drug, compare the pharmacy’s name and license first, then the price. The approved drug’s own prices are in Zepbound price, and FDA’s tiers are explained in the guide to compounded peptides. Why compounded semaglutide is not a generic either is in generic semaglutide.